{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.2","value":"31.5"},{"groupId":"OG001","spread":"20.1","value":"29.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"Apparent oral clearance unadjusted for bioavailability (CL/F) following a single dose of avapritinib","dispersionType":"Standard Deviation","groups":[{"description":"Part 1 and Part 2: Patients received a starting dose of 300 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG000","title":"Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD"},{"description":"Part 1 and Part 2: Patients received a starting dose of 400 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG001","title":"Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD"}],"paramType":"MEAN","populationDescription":"Patients enrolled in Part 1 or Part 2 with a starting dose of 300 or 400 mg QD and available PK samples","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1","title":"Apparent Oral Clearance Unadjusted for Bioavailability (CL/F)","type":"SECONDARY","unitOfMeasure":"L/h"}